Cogent Biosciences, Inc.
COGT
Classement en actions
#3227
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted... Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Prix de l'action
$31.49
Dernière synchronisation: 2026-10-21
Capitalisation boursière
$5.46B
Changement (1 jour)
0.81%
Changement (1 an)
112.08%
Pays
US
Échange Cogent Biosciences, Inc. (COGT)
Catégorie
Healthcare
Historique du prix de l'action pour Cogent Biosciences, Inc. (COGT)
Prix de clôture le plus élevé : $30.19 le 2026-10-01
Prix de clôture le plus bas : $44.44 le 2018-03-01
Prix de clôture le plus bas : $44.44 le 2018-03-01
Historique du prix de l'action de Cogent Biosciences, Inc. de 2018 à 2026
Performance annuelle du prix de l'action
| Année | Performance |
|---|---|
| 2026 (TTM) | -10.69% |
| 2025 | 364.44% |
| 2024 | 37.29% |
| 2023 | -46.89% |
| 2022 | 39.37% |
| 2021 | -29.74% |
| 2020 | 349.09% |
| 2019 | -87.13% |
| 2018 | 0.00% |
Prix de l'action pour des entreprises similaires ou concurrentes
| Entreprise | Prix de l'action | Variation 1a% | Pays |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $766.95 | 9.01% |
CH
|
